KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Exchange Rate Effect (2022 - 2025)

Recursion Pharmaceuticals' Exchange Rate Effect history spans 4 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Exchange Rate Effect rose 160.11% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $18.0 million, up 629.77%, while the annual FY2025 figure was $18.0 million, 629.77% up from the prior year.
  • Exchange Rate Effect reached $2.1 million in Q4 2025 per RXRX's latest filing, up from $1.9 million in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $9.3 million in Q2 2025 to a low of -$3.5 million in Q4 2024.
  • Average Exchange Rate Effect over 4 years is $1.1 million, with a median of $124000.0 recorded in 2023.
  • Peak YoY movement for Exchange Rate Effect: plummeted 10850.0% in 2024, then soared 7943.22% in 2025.
  • A 4-year view of Exchange Rate Effect shows it stood at -$307000.0 in 2022, then skyrocketed by 140.39% to $124000.0 in 2023, then tumbled by 2900.0% to -$3.5 million in 2024, then soared by 160.11% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Exchange Rate Effect are $2.1 million (Q4 2025), $1.9 million (Q3 2025), and $9.3 million (Q2 2025).